Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 13 of 13 publications.
Skip to main content
Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012 Dec;27(12):2429-37. doi: 10.1002/jbmr.1768
Gilsenan AW, Kellier N, Harris DH, Andrews EB, Masica DN. Linking a voluntary patient registry with US state cancer registries for possible signal detection. Poster presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 23, 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug 27; 21(suppl 3):464. doi: 10.1002/pds.3324
Harris DH, Gilsenan AW, Wu Y, Andrews EB. Using cancer surveillance data to advance science: monitoring for a potential safety signal for approved drugs through linkage studies. Poster presented at the Annual Meeting of the North American Association of Central Cancer Registries; 2012.
Chirila C, Gilligan TM, Gilsenan A, Price M, Hollis K, Calingaert B, Zografos L, Andrews E. A comparison of factors influencing patient knowledge: results across selected REMS surveys. Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 18, 2011. Chicago, IL.
Gilsenan A, Hollis K, Zografos L, Calingaert B, Andrews E. Examination of respondent bias and patient characteristics in multiple REMS assessment surveys. Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 18, 2011. Chicago, IL.
Gilsenan A, Harris DH, Midkiff K, Wright J, Andrews E. Linking with multiple state cancer registries for safety surveillance study – Is it feasible? Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 18, 2011. Chicago, IL.
Midkiff KD, Harris D, Gilsenan AW, Wu Y, Andrews EB. Drug safety studies using cancer registry data: confluence of elements impacting the interview response rate. Poster presented at the 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 14, 2011. Chicago, IL. [abstract] Pharmacoepidemiol Drug Saf. 2011 Aug 1; 20(Suppl. 1):S231. doi: 10.1002/pds.2206
Midkiff KD, Gilsenan AW, Wu Y, Harris DH, Masica D, Andrews EB. Using cancer registry data to advance the science of drug safety: results from an ongoing postmarketing drug safety surveillance study of adult osteosarcoma. Presented at the North American Association of Central Cancer Registries Annual Conference; June 21, 2011. Lexington, KY.
Mintz ML, Yawn BP, Mannino DM, Donohue JF, Hanania NA, Grellet CA, Gilsenan AW, McLeod LD, Dalal AA, Raphiou IH, Prillaman BA, Crater GD, Cicale MJ, Mapel DW. Prevalence of airway obstruction assessed by lung function questionnaire. Mayo Clin Proc. 2011 May 1;86(5):375-81.
Levitan BS, Andrews EB, Gilsenan A, Ferguson J, Noel RA, Coplan PM, Mussen F. Application of the BRAT framework to case studies: observations and insights. Clin Pharmacol Ther. 2011 Feb 1;89(2):217-24. doi: 10.1038/clpt.2010.280
Andrews EB, Midkiff KD, Gilsenan AW, Harris DH. Collaboration with multiple state cancer registries for a data linkage drug safety surveillance study – yes you can!. Poster presented at the North American Association of Central Cancer Registries Annual Conference; 2011.
Gilsenan AW, Midkiff KD, Harris DH. Opportunities for improving the use of cancer registry data in drug safety studies: factors influencing interview response rate. Presented at the North American Association of Central Cancer Registries Annual Conference; 2011.
Midkiff KD, Gilsenan AW, Harris DH, Wu Y, Masica D, Andrews EB. Exposure to possible osteosarcoma risk factors in a US postmarketing osteosarcoma surveillance study. Poster presented at the Scandinavian Sarcoma Group Annual Meeting; 2011.